Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...
The addition of two new members - Theratechnologies Inc. for Canada and Innovative Medicines Group (IMG) for LATAM - brings the total number of countries covered by WODA to 158 and extends its reach ...
In December 2024, NextCure announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for LNCB74. LNCB74 is being developed in partnership with LigaChem ...
The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately $4.25 million. Calidi ...
"Partnering with Carlson, Bison, George’s, and Craign Stein is an exciting step in our mission to provide more consumers with Yerbaé’s refreshing and energizing beverages," said Todd Gibson, CEO and ...
Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue. Management to Host ...
Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) testing in the National ...
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization. SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve ...
TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and ...
OrthoPediatrics’ CEO David Bailey commented “I’m especially proud of our newest clinic in Indy! As an Indiana-based company, being able to bring specialty care to KIDS in our Hoosier state represents ...
LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor cells with ...
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback